NPPA New Drug Prices: The National Pharmaceutical Pricing Authority (NPPA) has taken a big step to provide relief to common patients in the country from arbitrary prices of medicines. The authority has fixed the retail prices of 39 new medicines under the Drugs (Price Control) Order i.e. DPCO 2013. These include medicines used in the treatment of serious diseases like high blood pressure, diabetes, heart diseases, HIV, eye infections and cancer. This step has been taken with the intention of making these medicines more affordable for patients.
Order issued on July 8
This price notification was issued by the Department of Pharmaceuticals on July 8, 2026, which has been notified under paragraphs 5,11 and 15 of DPCO 2013. However, let us tell you that this order has been issued not to reduce the price of medicines already available in the market, but to fix the maximum retail price of new drug formulations. GST applicable on these prices will be charged separately.
Retail prices of many essential medicines fixed
In the list released by NPPA, the retail price of Amlodipine+Bisoprolo+Telmisartan tablets used in the treatment of high blood pressure has been fixed at Rs 14.74 per tablet. The price of Nepafenac+Moxifloxacin Ophthalmic Solution medicines, used after eye surgery and in the treatment of bacterial infections, has been fixed at Rs 68.64 per ml. Whereas the price of Clopidogrel + Aspirin + Atorvastatin capsules, given to reduce the risk of heart attack and stroke, has been fixed at Rs 6.37 per capsule. The prices of many fixed dose combination medicines used in the treatment of diabetes have also been fixed in the list. These include medicines based on Dapagliflozin, Empagliflozin, Sitagliptin, Metformin, Glimepiride and Voglibose.
Apart from this, the prices of medicines like Amoxicillin+Clavulanate tablets and dispersible tablets used in the treatment of infections, eye drops used in the treatment of glaucoma, HIV therapy kit, Vitamin D3 oral solution and Imatinib Oral Solution used in the treatment of cancer have also been fixed. Apart from this, Tenecteplase (TNK-tpa) Injection 50mg is also included among the most expensive medicines in the list of NPPA. The retail price of the injection used in the treatment of heart attack has been fixed at Rs 60,238.27 per vial.
It is mandatory for shopkeepers to show price list
NPPA has once again clarified that it is mandatory for all retailers and dealers to clearly display the price list issued by the manufacturing companies in their shops. Citing Para 24 (4) of DPCO 2013, the authority said that every retailer and dealer will have to display the price list and supplementary price list in such a part of his shop from where any customer will be able to easily see and know it.
Also read-Explained: One basil insulin and complete week off from diabetes! Know when, where and how will you get 40% cheaper medicine?
Action will be taken if charging more than the fixed price
It has also been made clear in the notification that if any manufacturer or marketing company does not adhere to the notified retail price, then it will have to deposit the excess amount recovered with the government. According to NPPA, if the retail price of these medicines is not fixed as per this order and the notice given therein, then the concerned company will have to deposit the excess amount recovered with interest under the provisions of DPCO 2013 and Essential Commodities Act 1955.
Also read-Cancer Risk: Sitting continuously for more than 30 minutes can increase the risk of cancer, claims new research, know the reason for this.
Check out below Health Tools-
Calculate Your Body Mass Index (BMI)
Calculate The Age Through Age Calculator
